Expression and Crucial Role of Long Non-coding RNA FGD5-AS1 in Human Cancers

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2021 Nov 17

PMID 34786036

Citations 1

Authors

Lixu Zhu

Xiaoyi Shi

Xiao Yu

Zhihui Wang

Menggang Zhang

Yuting He

Wenzhi Guo

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (lncRNAs) are transcribed by RNA polymerase II and are longer than 200 nucleotides. Several studies have revealed that lncRNAs are important regulators of cancer progression. The lncRNA FGD5-AS1, first identified in 2018, has emerged as a crucial regulator of processes related to carcinogenesis. The expression levels of FGD5-AS1 are known to be significantly up-regulated in a variety of human cancers. Moreover, FGD5-AS1 expression closely correlates with clinical features and poor prognosis and its expression has been shown to attenuate cell proliferation, cell migration, cell invasiveness, drug resistance, and the epithelial-mesenchymal transition through several pathways. Here, we provide an overview of the role of FGD5-AS1 in various cancers and discuss its potential clinical utility in tumor progression. In addition, we used a gene expression profiling interactive analysis dataset to explore associations between FGD5-AS1 pan-cancer expressions and prognoses.

Citing Articles

Identification and multi-omics analysis of essential coding and long non-coding genes in colorectal cancer.

Li Y, Meng Z, Fan C, Rong H, Xi Y, Liao Q Biochem Biophys Rep. 2025; 41:101938.

PMID: 40034256 PMC: 11874739. DOI: 10.1016/j.bbrep.2025.101938.

The prognostic significance of lncRNA FGD5-AS1 in various malignancies: a meta-analysis.

Lei H, Ye T, Sun J, Wang Y Front Oncol. 2024; 14:1451949.

PMID: 39224806 PMC: 11366646. DOI: 10.3389/fonc.2024.1451949.

References

Ni W, Zhang Y, Zhan Z, Ye F, Liang Y, Huang J . A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. J Hematol Oncol. 2017; 10(1):91. PMC: 5395742. DOI: 10.1186/s13045-017-0449-4. View

Arnold M, Karim-Kos H, Coebergh J, Byrnes G, Antilla A, Ferlay J . Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 2013; 51(9):1164-87. DOI: 10.1016/j.ejca.2013.09.002. View

Tang F, Xu Y, Wang H, Bian E, Zhao B . LncRNA-ATB in cancers: what do we know so far?. Mol Biol Rep. 2020; 47(5):4077-4086. DOI: 10.1007/s11033-020-05415-5. View

Gelatti A, Drilon A, Santini F . Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019; 137:113-122. PMC: 7478849. DOI: 10.1016/j.lungcan.2019.09.017. View

Hughes D, Andersson D . Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015; 16(8):459-71. DOI: 10.1038/nrg3922. View

Liao W, Fan S, Zheng Y, Liao S, Xiong Y, Li Y . Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review. Curr Med Chem. 2018; 26(31):5862-5874. DOI: 10.2174/0929867325666180514113136. View

Fu J, Cai H, Wu Y, Fang S, Wang D . Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene. 2020; 755:144886. DOI: 10.1016/j.gene.2020.144886. View

Ramnarine V, Kobelev M, Gibb E, Nouri M, Lin D, Wang Y . The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. Eur Urol. 2019; 76(5):546-559. DOI: 10.1016/j.eururo.2019.07.040. View

Topper M, Vaz M, Marrone K, Brahmer J, Baylin S . The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2019; 17(2):75-90. PMC: 7254932. DOI: 10.1038/s41571-019-0266-5. View

10.

Lv J, Li Q, Ma R, Wang Z, Yu Y, Liu H . Long Noncoding RNA FGD5-AS1 Knockdown Decrease Viability, Migration, and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells by Regulating the MicroRNA-944/MACC1 Axis. Technol Cancer Res Treat. 2021; 20:1533033821990090. PMC: 7887693. DOI: 10.1177/1533033821990090. View

11.

Gao Y, Zhu H, Mao Q . Expression of lncRNA FGD5-AS1 correlates with poor prognosis in melanoma patients. J Gene Med. 2020; 22(12):e3278. DOI: 10.1002/jgm.3278. View

12.

Wu S, Kallin E, Zhang Y . Role of H3K27 methylation in the regulation of lncRNA expression. Cell Res. 2010; 20(10):1109-16. PMC: 2949548. DOI: 10.1038/cr.2010.114. View

13.

Yang Y, Dong M, Hu H, Min Q, Xiao L . LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and metastasis of renal cell carcinoma through ERK/AKT signalling. Eur Rev Med Pharmacol Sci. 2020; 24(17):8756-8766. DOI: 10.26355/eurrev_202009_22814. View

14.

Chen J, Yang H, Teo A, Amer L, Sherbaf F, Tan C . Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020; 52(2):177-186. DOI: 10.1038/s41588-019-0569-6. View

15.

Liu G, Pei F, Yang F, Li L, Amin A, Liu S . Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. Int J Mol Sci. 2017; 18(2). PMC: 5343902. DOI: 10.3390/ijms18020367. View

16.

Herrmann J . Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020; 17(8):474-502. PMC: 8782611. DOI: 10.1038/s41569-020-0348-1. View

17.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

18.

Gao G, Jiang Y, Jia H, Sun W, Guo Y, Yu X . From perinuclear to intranuclear localization: A cell-penetrating peptide modification strategy to modulate cancer cell migration under mild laser irradiation and improve photothermal therapeutic performance. Biomaterials. 2019; 223:119443. DOI: 10.1016/j.biomaterials.2019.119443. View

19.

Yoon Y, Han Y, Choi J, Lee Y, Yun J, Lee S . Benproperine, an ARPC2 inhibitor, suppresses cancer cell migration and tumor metastasis. Biochem Pharmacol. 2019; 163:46-59. DOI: 10.1016/j.bcp.2019.01.017. View

20.

Sreekumar A, Poisson L, Rajendiran T, Khan A, Cao Q, Yu J . Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457(7231):910-4. PMC: 2724746. DOI: 10.1038/nature07762. View